# A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.

> **NCT06850051** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 270 (actual)

## Conditions studied

- Healthy Volunteers
- Influenza Vaccination
- Respiratory Syncytial Virus Vaccination
- Parainfluenza Vaccination
- Human Metapneumovirus Vaccination

## Interventions

- **BIOLOGICAL:** TIV-HA Vaccine formulation 1 at low dose
- **BIOLOGICAL:** TIV-HA formulation 1 at high dose
- **BIOLOGICAL:** TIV-HA formulation 2 at low dose
- **BIOLOGICAL:** TIV-HA formulation 2 at high dose
- **BIOLOGICAL:** RSV/hMPV/PIV3 formulation 2 at low dose
- **BIOLOGICAL:** RSV/hMPV/PIV3 formulation 1 at high dose
- **BIOLOGICAL:** RSV/hMPV/PIV3 formulation 2 at high dose
- **BIOLOGICAL:** RSV/hMPV/PIV3 formulation 1 at low dose
- **BIOLOGICAL:** RIV4 (Supemtek®)

## Key facts

- **NCT ID:** NCT06850051
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-03-19
- **Primary completion:** 2025-12-11
- **Final completion:** 2025-12-11
- **Target enrollment:** 270 (ACTUAL)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06850051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06850051, "A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT06850051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*